
    
      Ranolazine was approved as Ranexa in the United States on January 31, 2006 for the treatment
      of chronic angina. This post-marketing study is a single-center, double-blind, prospective,
      randomized, parallel-group evaluation of patients randomized 1:1 between Ranolazine and
      placebo.
    
  